Ontology highlight
ABSTRACT:
SUBMITTER: Lipson EJ
PROVIDER: S-EPMC3575079 | biostudies-literature | 2011 Nov
REPOSITORIES: biostudies-literature
Lipson Evan J EJ Drake Charles G CG
Clinical cancer research : an official journal of the American Association for Cancer Research 20110907 22
Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overal ...[more]